

Supporting Information

The Influence of Hydrophobic Chains in Nanocarriers on Antitumor Efficacy of Docetaxel Nanoparticles

Zhengqi Dong,^a Yiping Shen,^{a,b} Shuang Zhao,^{a,b} Xiangtao Wang,^a Meihua Han,^a Ning Zhao,^c Hui Ao,^a Yifei Guo^{a,*}

^a Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 151, Malianwa North Road, Haidian District, Beijing 100193, China

^b Research Center on Life Sciences and Environmental Sciences, Harbin University of Commerce, No. 138, Tongda Street, Daoli District, Harbin 150076, China



^c Department of Pharmacy, Xiyuan Hospital, China Academy of Chinese Medical Sciences, No.1, Xiyuancaochang, Haidian District, Beijing 100091, China

Table S1. Conditions and results for DTX-loaded nanoparticles.

Nanocarrier	DTX:nanocarrier (mg:mg)	Yield (%)	DLC (%)	EE (%)
PEG ₄₅ PCL ₁₇	4:16	68	12.6	42.8
PEG ₄₅ PCL ₁₇	4:8	69	24.1	49.8
PEG ₄₅ PCL ₁₇	8:4	65	49.8	48.5
PEG ₄₅ PCL ₁₇	16:4	58	60.1	43.5
PEG ₄₅	4:16	59	13.4	39.5
PEG ₄₅	4:8	61	19.9	36.4
PEG ₄₅	8:4	60	34.9	31.4
PEG ₄₅	16:4	52	58.4	37.9

Table S2. GPC results for PEG₄₅PCL₁₇ in different solutions with different incubation times

Time	H ₂ O		saline		Glucose		PBS	
e	Mn	PDI	Mn	PDI	Mn	PDI	Mn	PDI
3 d	5398	1.17	5519	1.20	5347	1.15	5255	1.16
7 d	5387	1.17	5291	1.18	5521	1.16	5075	1.22

Figure S1. Molar mass distribution curves for PEG₄₅PCL₁₇ in different media after incubation for 3 d (a) and 7 d (b) at 37 °C. The black curve represents the original solid PEG₄₅PCL₁₇.Figure S2. Tumor volume change curves for the glucose solution group, PTX injection group, and DTX injection group. (mean \pm SD, n = 8)